Trial Profile
A Phase I Dose Escalating Study to Evaluate TKI258 Administered Orally on a 5 Days on/2days Off Schedule in Japanese Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Apr 2016
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 19 Nov 2011 New trial record